Exciting Developments for Atossa Therapeutics at Upcoming Symposium
SEATTLE, November 2024 – Atossa Therapeutics, Inc. (NASDAQ: ATOS), a biopharmaceutical company known for its innovative approach in treating breast cancer, is gearing up to share groundbreaking research on (Z)-endoxifen at the upcoming San Antonio Breast Cancer Symposium (SABCS). This symposium is an essential gathering, taking place from December 10 to December 13, where experts from around the globe unite to discuss advancements in the fight against breast cancer.
Atossa will present five pivotal abstracts that delve into the efficacy and safety of (Z)-endoxifen, a novel therapeutic agent under investigation for its potent effects in breast cancer management. These presentations are expected to provide valuable insights into both the prevention of breast cancer and its treatment, showcasing promising data gathered from various clinical studies.
Highlights of (Z)-Endoxifen Research
There is palpable excitement within Atossa’s leadership regarding these upcoming presentations. Dr. Steven Quay, the President and CEO, stated, “We are thrilled to showcase our research on (Z)-endoxifen at SABCS 2024. This work underscores our dedication to advancing treatment options that can significantly impact patients battling breast cancer.”
Featured Presentations at SABCS
Among the abstracts being presented, several studies stand out:
1. Primary Breast Cancer Prevention Using Oral Endoxifen
This study evaluates how low-dose (Z)-endoxifen can effectively reduce mammographic breast density, a known risk factor for developing breast cancer. The discussion will take place during Poster Spotlight Session 16, presented by Per Hall from the Karolinska Institutet on December 12.
2. Quality of Life in Premenopausal Patients
A significant focus of the data will be on the quality of life for premenopausal women with estrogen receptor-positive breast cancer undergoing treatment with (Z)-endoxifen. This evaluation includes findings from the EVANGELINE study, and will be addressed by Sarah Premji.
3. Pharmacokinetics of (Z)-Endoxifen
The PK profile of (Z)-endoxifen provides critical information regarding its dosing strategy and safety profile. Matthew Goetz will discuss these results and their implications for optimizing treatment approaches.
4. Synergistic Treatment Findings
Another intriguing aspect lies in the exploration of molecules that work synergistically with (Z)-endoxifen, potentially enhancing its effectiveness against breast cancer. Daniela Huhn will present these findings on December 13.
5. Comparing Treatment Effectiveness
A randomized phase 2 trial will examine the non-inferiority of (Z)-endoxifen versus exemestane plus goserelin in treating ER+/HER2- breast cancer. This research is vital for understanding how to minimize ovarian function suppression in treatment.
The Science Behind (Z)-Endoxifen
(Z)-endoxifen represents a significant scientific advancement; it acts as a selective estrogen receptor modulator (SERM) that not only inhibits estrogen receptors but also induces their degradation. This mechanism of action makes (Z)-endoxifen particularly powerful, especially in patients who exhibit resistance to conventional hormonal therapies.
Moreover, one of the unique features of (Z)-endoxifen is its ability to target PKC?1, a cancer-promoting protein, ensuring that the treatment can work effectively at levels achievable through regular dosing. Compared to traditional therapies like tamoxifen, (Z)-endoxifen has shown a more favorable profile in terms of bone health while minimizing endometrial proliferation.
Atossa’s Innovation in Formulation
Atossa is dedicated to enhancing patient care through the development of a proprietary oral formulation of (Z)-endoxifen. Unlike other formulations, it bypasses liver metabolism, which helps achieve therapeutic blood concentrations more effectively. Initial studies suggest that this formulation is well tolerated, marking a significant step forward in treating breast cancer.
About Atossa Therapeutics
Atossa Therapeutics is at the forefront of biopharmaceutical innovation, focusing entirely on unmet medical needs in oncology, specifically in breast cancer treatment and prevention through the use of (Z)-endoxifen. For more details about the company's initiatives, please refer to their official website, where they share extensive resources and updates on their ongoing research.
Frequently Asked Questions
What is (Z)-endoxifen?
(Z)-endoxifen is a highly effective selective estrogen receptor modulator used in breast cancer treatment and prevention, showing promise in clinical studies.
What are the main focuses of Atossa's research?
Atossa’s research centers on developing innovative treatments for breast cancer, particularly through the utilization of (Z)-endoxifen.
Where will Atossa be presenting its findings?
Atossa will present its findings at the San Antonio Breast Cancer Symposium (SABCS). This is a key event in the oncology field.
Who is leading the research at Atossa?
The research initiatives and presentations are being led by various professionals, including Dr. Steven Quay, the President and CEO.
How can the public learn more about Atossa’s research?
More information about Atossa Therapeutics, including news and research, can be found on their official website.
